- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04047043
Evaluation of Serum Taurine as a Prognostic Marker for Graft Function in Adult Egyptian Patients Undergoing Living Donor Liver Transplant (Taurine/LDLT)
Evaluation of Serum Taurine as a Prognostic Marker for Graft Function in Adult Egyptian Patients Undergoing Living Donor Liver Transplant : A Prospective Study
Study Overview
Detailed Description
- All selected adult patients undergoing LDLT will be admitted to the ICU post LDLT
- Preoperative assessment and preparation will be done according to the standard protocol of the hospital. After full clinical examinations using MELD score corrected for serum sodium level ), imaging techniques (Abdominal U.S; abdominal triphasic CAT Scan, liver biopsy, CT volumetry, upper and lower GIT endoscopy, CT chest, bone scan in HCC patients, renal scan in patients with urinary creatinine clearance < 60 ml/min), pulmonary function test, carotid duplex and dobutamine ECHO will be done for all recipients .
- Serum level of AST, ALT, bilirubin, albumin, ALP, GGT, prothrombin, INR, partial thrombin time, factor V, fasting blood glucose, CBC, CRP, Procalcitonin, urea, creatinine, urinary creatinine clearance, serum electrolytes, urine and stool analysis will be done for all patients.
- Analysis of serum levels of specific liver tumor markers including AFP, beside taurine as a possible new marker will be done for all patients .
- HCV and HBV will be detected for all patients by PCR technique.
- CMV IgM , EBV IgM ,HSV IgM will be done for all patients.
- After 12 hours fasting, 10 ml of venous blood will be collected, in plain tube and allowed to clot for 1/2 an hour. Then, it will be centrifuged at 3,000 rpm for 10 min. The serum will be separated and stored at -20 Cº to avoid loss of biological activity until the batch analysis for serum taurine which will be measured four times for the recipient ( preoperative before induction of anesthesia , 7, 14 days and 30 days post transplant ) by high performance liquid chromatography (HPLC) .
Recipient patients will be divided into 3 groups according to preoperative serum taurine .
- Group 1 ( > 30 μmol/L) (20 cases)
- Group 2 (30-20 μmol/L) (20 cases)
- Group 3 (< 20 μmol/L ) (20 cases)
Intraoperatively, both standard anesthetic and piggyback techniques for hepatic transplantation will be performed by the same anesthesia and surgical team who will be blinded to study medication. Intraoperative blood loss, graft weight, graft weight to recipient weight ratio (GWRWR), blood products transfused, and intraoperative adverse events will be recorded. At the end of surgery, patients will be transferred to the ICU and will be monitored and receive the standard protocol for postoperative management after liver transplantation .
All patients will be assessed for primary graft function (PGF) on a daily basis during the first week post-transplant. Primary graft dysfunction includes one or more of the following variables: (1) bilirubin ≥10 mg/dL on postoperative day 7; (2) INR ≥1.6 on postoperative day 7; and (3) ALT or AST >2000 IU/L within 7 postoperative days.
The primary outcome include correlation between serum taurine levels ( μmol/L) of recipients and graft function which will be detected by liver profile. Secondary outcomes include 30 days mortality (days), the duration of ICU and hospital stays (days) and any recorded post operative complications.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Ain Shams University Specialized Hospital
-
Cairo, Ain Shams University Specialized Hospital, Egypt
- Hanaa El Gendy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Recipient age ≥18 years.
- Donor age between 18 and 45 years
- ABO group compatibility with the recipient
- Normal psychological workup.
Exclusion Criteria:
- Recipients patients with pre-existing renal failure requiring hemodialysis or continuous hemofiltration, glomerular filtration rate ≤ 30 ml /min by renal scan, ..
- Re-transplant
- HA1C > 7%
- Pregnancy.
- Donors with fatty liver.
- Estimated remnant liver volume for donor is < 30% of total liver volume.
- Donor body mass index > 28 kg/m².
- Donor with abnormal biliary anatomy.
- Donor with steatosis > 10%.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Taurine > 30 μmol/L
serum taurine level
|
blood sample for serum taurine level
|
Taurine 30-20 μmol/L
serum taurine level
|
blood sample for serum taurine level
|
Taurine < 20 μmol/L
serum taurine level
|
blood sample for serum taurine level
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Taurine level in micro mol/L
Time Frame: 7 months
|
Taurine level preoperative, 7th,14 th and 30 days post liver transplantation will be assesd and correlated with graft function
|
7 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seventh day syndrome, 30 days mortality (days), the duration of ICU and hospital stays (days).
Time Frame: 7 months
|
Taurine level will be correlated with these parameters
|
7 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- IRB 0006379
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Taurine
-
Ain Shams UniversityCompleted
-
Third Military Medical UniversityUnknownDiabetes | Taurine | Lower Extremity Artery DiseaseChina
-
Third Military Medical UniversityUnknownDiabetes Mellitus | Cognitive Decline | TaurineChina
Clinical Trials on serum taurine
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Coordenação de Aperfeiçoamento...Completed
-
Zhiming ZhuCompletedPrehypertensionChina
-
Ain Shams UniversityCompleted
-
University of Illinois at ChicagoNational Cancer Institute (NCI); Rush University Medical CenterActive, not recruitingColorectal CancerUnited States
-
Hospital de Clinicas de Porto AlegreRecruitingDiabetes Mellitus, Type 2Brazil
-
Cambridge Health AllianceStanley Medical Research Institute; Mclean HospitalTerminated
-
Hamad Medical CorporationUnknownit is a Group of Metabolic Diseases in | Which a Person Has High Blood Sugar, Either | Because the Body Does Not Produce Enough Insulin, | or Because Cells do Not Respond to the Insulin That | is Produced.
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Coordenação de Aperfeiçoamento...Not yet recruiting
-
University Health Network, TorontoRecruitingThalassemia MajorCanada